Top 50 Companies Ranked By Healthcare Revenue

Healthcare Healthcare Consolidated Consolidated Net Income/ Net Income/ Earnings/(Loss) Earnings/(Loss) Per Shareholders’ Shareholders’ Rank 2012 Company Total Assets 2012 Total Assets 2011 Company Revenue 2012 Revenue 2011 Revenue 2012 Revenue 2011 (Loss) 2012 (Loss) 2011 Per Share 2012 Share 2011 Equity 2012 Equity 2011

1 Johnson & Johnson $67,224,000,000 $65,030,000,000 $67,224,000,000 $65,030,000,000 $10,853,000,000 $9,672,000,000 $3.86 $3.49 $121,347,000,000 $113,644,000,000 $64,826,000,000 $57,080,000,000 Johnson & Johnson

2 Inc. 58,986,000,000 65,259,000,000 58,986,000,000 65,259,000,000 14,570,000,000 10,009,000,000 1.94 1.27 185,798,000,000 188,002,000,000 81,260,000,000 82,190,000,000 Pfizer Inc.

3 AG 56,673,000,000 58,566,000,000 56,673,000,000 58,566,000,000 9,618,000,000 9,245,000,000 3.89 3.78 124,216,000,000 117,496,000,000 69,219,000,000 65,940,000,000 Novartis AG

4 F. Hoffmann-La Roche Ltd. 48,521,915,325 45,356,723,899 48,521,915,325 45,356,723,899 10,422,309,907 10,178,095,340 11.90 11.71 69,110,589,741 65,667,057,694 15,456,969,180 12,898,581,636 F. Hoffmann-La Roche Ltd.

5 Merck & Co. 47,267,000,000 48,047,000,000 47,267,000,000 48,047,000,000 6,168,000,000 6,272,000,000 2.00 2.02 106,132,000,000 105,128,000,000 55,463,000,000 56,943,000,000 Merck & Co.

6 44,938,347,300 42,934,915,100 44,938,347,300 42,934,915,100 6,387,065,300 7,320,628,700 4.81 5.52 129,113,361,300 129,448,981,200 73,730,934,200 72,271,437,700 Sanofi

7 GlaxoSmithKline plc 41,901,064,300 43,416,611,100 41,901,064,300 43,416,611,100 7,236,894,500 8,340,263,300 1.45 1.64 65,750,317,500 65,124,124,000 9,210,593,000 12,733,129,600 GlaxoSmithKline plc

8 39,873,910,000 38,851,259,000 39,873,910,000 38,851,259,000 5,962,900,000 4,728,449,000 3.72 3.01 67,234,944,000 60,276,893,000 26,813,232,000 24,526,145,000 Abbott Laboratories

9 AstraZeneca plc 27,973,000,000 33,591,000,000 27,973,000,000 33,591,000,000 6,327,000,000 10,016,000,000 4.98 7.30 53,534,000,000 52,830,000,000 23,952,000,000 23,472,000,000 AstraZeneca plc

10 Bayer AG 23,933,170,800 22,077,617,100 51,127,384,000 46,971,355,200 3,145,311,400 3,176,173,000 3.81 3.84 66,012,962,400 67,850,513,500 23,877,877,100 24,780,578,900 Bayer AG

11 Eli Lilly and Co. 22,603,400,000 24,286,500,000 22,603,400,000 24,286,500,000 4,088,600,000 4,347,700,000 3.66 3.90 34,398,900,000 33,659,800,000 14,773,900,000 13,535,600,000 Eli Lilly and Co.

12 Teva Pharmaceutical Industries Ltd. 20,317,000,000 18,312,000,000 20,317,000,000 18,312,000,000 1,963,000,000 2,759,000,000 2.25 3.09 50,609,000,000 50,142,000,000 22,867,000,000 22,343,000,000 Teva Pharmaceutical Industries Ltd.

13 Boehringer Ingelheim GmbH 18,891,156,900 16,936,588,900 18,891,156,900 16,936,588,900 1,590,658,300 1,897,988,400 N/A N/A 22,233,211,000 23,992,322,200 7,944,290,200 9,600,529,400 Boehringer Ingelheim GmbH

14 Bristol-Myers Squibb Co. 17,621,000,000 21,244,000,000 17,621,000,000 21,244,000,000 1,960,000,000 3,709,000,000 1.16 2.16 35,897,000,000 32,970,000,000 13,638,000,000 15,867,000,000 Bristol-Myers Squibb Co.

15 Inc. 17,265,000,000 15,582,000,000 17,265,000,000 15,582,000,000 4,345,000,000 3,683,000,000 5.52 4.04 54,298,000,000 48,871,000,000 19,060,000,000 19,029,000,000 Amgen Inc.

16 Takeda Pharmaceutical Co. 15,532,299,251 15,024,649,151 16,432,067,110 15,922,042,841 1,384,868,629 1,310,140,340 1.75 1.66 41,738,936,372 37,744,328,374 24,748,855,123 24,970,412,578 Takeda Pharmaceutical Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

17 Inc. 14,190,000,000 13,893,000,000 14,190,000,000 13,893,000,000 2,326,000,000 2,224,000,000 4.18 3.88 20,390,000,000 19,073,000,000 6,938,000,000 6,585,000,000 Baxter International Inc.

18 Novo Nordisk A/S 13,470,874,624 11,454,369,670 13,470,874,624 11,454,369,670 3,700,148,476 2,951,728,186 6.71 5.18 11,337,488,346 11,169,849,107 7,014,951,141 6,465,246,366 Novo Nordisk A/S

19 Otsuka Holdings Co. 12,129,597,974 11,462,266,540 12,852,748,760 12,182,895,431 1,291,853,962 972,607,365 2.34 1.74 18,773,947,452 17,587,496,043 14,160,979,213 13,376,933,629 Otsuka Holdings Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

20 Astellas Pharma Inc. 10,611,068,904 10,228,838,240 10,611,068,904 10,228,838,240 874,232,35 825,472,196 1.90 1.79 15,253,360,768 14,779,244,487 11,871,351,694 12,149,699,272 Astellas Pharma Inc. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

21 Co. 10,529,197,003 9,904,790,546 10,529,197,003 9,904,790,546 702,975,625 109,559,987 0.16 0.16 17,348,010,974 16,022,781,471 9,575,540,783 9,317,769,336 Daiichi Sankyo Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

22 Inc. 9,702,517,000 8,385,385,000 9,702,517,000 8,385,385,000 2,591,566,000 2,803,637,000 1.64 1.77 21,239,838,000 17,303,134,000 9,550,869,000 6,867,349,000 Gilead Sciences Inc.

23 Merck KGaA 8,847,506,360 8,250,591,580 14,367,232,110 13,214,422,760 744,536,100 794,686,200 3.36 3.59 27,831,119,470 28,446,551,210 13,323,724,260 13,435,083,200 Merck KGaA

24 Inc. 6,796,110,000 6,129,825,000 6,796,110,000 6,129,825,000 640,850,000 536,810,000 1.52 1.22 11,931,897,000 11,598,143,000 6,231,450,000 5,393,212,000 Mylan Inc.

25 Inc. 5,914,900,000 4,584,400,000 5,914,900,000 4,584,400,000 97,300,000 260,900,000 0.76 2.06 14,103,500,000 6,698,300,000 3,856,400,000 3,562,500,000 Actavis Inc.

26 Inc. 5,806,100,000 5,419,100,000 5,806,100,000 5,419,100,000 1,098,800,000 934,500,000 3.58 3.01 9,179,300,000 8,508,600,000 5,837,100,000 5,309,600,000 Allergan Inc.

27 Co. 5,795,251,662 6,407,449,615 6,053,160,283 6,837,353,593 509,391,158 617,400,021 1.79 2.17 10,448,971,193 10,601,034,083 5,004,779,994 4,467,943,442 Eisai Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

28 Idec Inc. 5,516,461,000 5,048,634,000 5,516,461,000 5,048,634,000 1,380,033,000 1,234,428,000 5.76 5.04 10,130,118,000 9,049,604,000 6,961,523,000 6,425,499,000 Biogen Idec Inc.

29 Celgene Corp. 5,506,713,000 4,842,070,000 5,506,713,000 4,842,070,000 1,456,180,000 1,317,456,000 3.30 2.85 11,734,306,000 10,005,910,000 5,694,467,000 5,512,727,000 Celgene Corp.

30 CSL Ltd. 5,130,000,000 4,814,000,000 5,130,000,000 4,814,000,000 1,216,000,000 1,024,000,000 2.43 1.97 5,976,000,000 5,901,000,000 3,007,000,000 3,477,000,000 CSL Ltd. (June 13) (June 12) (June 13) (June 12) (June 13) (June 12) (June 13) (June 12) (June 13) (June 12) (June 13) (June 12)

31 Chugai Pharmaceutical Co. 4,901,277,875 4,679,491,356 4,901,277,875 4,679,491,356 603,933,851 441,430,719 1.11 0.81 7,363,066,901 6,683,575,545 6,209,145,577 5,875,695,314 Chugai Pharmaceutical Co.

32 Shire plc 4,681,200,000 4,263,400,000 4,681,200,000 4,263,400,000 745,400,000 865,000,000 1.31 1.51 7,317,200,000 6,380,200,000 3,809,200,000 3,185,000,000 Shire plc

33 UCB S.A. 4,451,785,800 4,174,031,400 4,451,785,800 4,174,031,400 324,046,800 306,044,200 1.81 1.70 12,036,024,000 11,799,418,400 5,907,424,600 6,042,444,100 UCB S.A.

34 Mitsubishi Tanabe Pharma Corp. 4,375,709,613 4,194,987,865 4,423,119,131 4,296,254,089 442,038,620 411,670,360 0.79 0.73 9,146,079,983 8,651,735,781 7,853,962,224 7,648,707,397 Mitsubishi Tanabe Pharma Corp. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

35 Inc. 4,092,100,000 4,057,100,000 4,092,100,000 4,057,100,000 44,200,000 (9,400,000) 0.27 (0.06) 6,088,600,000 5,779,100,000 3,041,700,000 2,938,000,000 Hospira Inc.

36 Valeant Pharmaceuticals International Inc. 3,546,626,000 2,463,450,000 3,546,626,000 2,463,450,000 (116,025,000) 159,559,000 (0.38) 0.49 17,950,379,000 13,108,119,000 3,717,398,000 3,929,830,000 Valeant Pharmaceuticals International Inc.

37 Grifols S.A. 3,370,271,890 2,308,978,757 3,370,271,890 2,308,978,757 328,389,284 64,588,185 0.96 0.21 7,236,368,817 7,252,476,000 2,418,444,852 2,141,015,785 Grifols S.A.

38 Dainippon Sumitomo Pharma Co. 3,241,521,579 3,271,721,009 3,669,135,802 3,697,319,827 105,972,354 91,052,021 0.27 0.23 6,407,291,337 5,902,817,347 3,652,685,449 3,622,190,567 Dainippon Sumitomo Pharma Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

39 Kyowa Hakko Kirin Co. 3,130,681,533 2,873,202,205 4,173,866,199 4,306,213,981 303,169,632 320,821,849 0.55 0.57 8,510,924,580 8,254,485,091 7,024,091,706 6,951,340,516 Kyowa Hakko Kirin Co.

40 Inc. 3,126,125,000 4,586,044,000 3,126,125,000 4,586,044,000 (32,103,000) 979,058,000 (0.12) 3.57 7,629,582,000 7,491,755,000 5,745,255,000 5,676,817,000 Forest Laboratories Inc. (March 13) (March 12) (March 13) (March 12) March 13 (March 12) March 13 (March 12) (March 13) (March 12) (March 13) (March 12)

41 Endo Health Solutions Inc. 3,027,363,000 2,730,121,000 3,027,363,000 2,730,121,000 (740,337,000) 187,613,000 (6.40) 1.55 6,568,559,000 7,292,583,000 1,133,206,000 2,039,591,000 Endo Health Solutions Inc.

42 Taisho Pharmaceutical Co. 3,009,053,498 2,861,981,640 3,009,053,498 2,861,981,640 277,725,018 257,011,713 3.43 3.13 7,137,153,108 6,642,460,694 6,100,643,664 5,683,929,514 Taisho Pharmaceutical Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

43 & Co. 2,985,153,530 2,820,249,024 2,985,153,530 2,820,249,024 704,094,123 285,966,023 2.10 0.85 6,066,075,762 5,509,771,025 4,524,343,147 3,961,549,013 Shionogi & Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

44 H. A/S 2,555,505,680 2,763,544,077 2,555,505,680 2,763,544,077 201,132,558 394,150,754 1.03 2.01 3,722,765,098 3,545,112,393 2,278,581,541 2,205,724,940 H. Lundbeck A/S

45 Warner Chilcott plc 2,541,000,000 2,728,106,000 2,541,000,000 2,728,106,000 403,000,000 171,146,000 1.61 0.67 4,218,000,000 5,030,029,000 (600,000,000) 69,131,000 Warner Chilcott plc

46 Stada Arzneimittel AG 2,362,841,250 2,205,827,716 2,362,841,250 2,205,827,716 111,230,350 28,336,092 1.88 0.48 3,834,598,807 3,600,320,686 1,159,196,415 1,098,042,869 Stada Arzneimittel AG

47 Ranbaxy Laboratories Ltd. 2,295,839,236 1,868,091,062 2,295,839,236 1,868,091,062 172,899,382 (543,325,651) 0.41 (1.29) 1,247,215,852 1,479,358,628 359,933,858 360,532,884 Ranbaxy Laboratories Ltd.

48 Sun Pharmaceutical Industries Ltd. 2,076,306,114 1,473,598,430 2,076,306,114 1,473,598,430 552,719,535 488,156,640 0.53 0.47 3,868,312,787 3,027,034,576 2,758,899,287 2,248,277,839 Sun Pharmaceutical Industries Ltd. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

49 Meda AB 1,918,311,897 1,898,377,165 1,918,311,897 1,898,377,165 174,244,326 237,444,810 0.59 0.79 5,397,882,488 5,717,281,198 2,231,656,355 2,210,687,970 Meda AB

50 Pharmaceuticals Ltd. 1,843,229,178 1,915,391,916 1,843,229,178 1,915,391,916 323,372,081 (156,040,311) 2.74 (1.31) 2,873,292,098 2,913,594,966 1,619,541,431 1,610,807,294 Actelion Pharmaceuticals Ltd.

Notes: N/A = Not applicable; March 13 = fiscal year ended March 31, 2013; March 12 = March 31, 2012; June 13 = June 30, 2013; June 12 = June 30, 2012; For more details about this information, please see the Notes and Methodology on page 8.

10 • Med Ad News October 2013 Top 50 Companies Ranked By Healthcare Revenue

Healthcare Healthcare Consolidated Consolidated Net Income/ Net Income/ Earnings/(Loss) Earnings/(Loss) Per Shareholders’ Shareholders’ Rank 2012 Company Total Assets 2012 Total Assets 2011 Company Revenue 2012 Revenue 2011 Revenue 2012 Revenue 2011 (Loss) 2012 (Loss) 2011 Per Share 2012 Share 2011 Equity 2012 Equity 2011

1 Johnson & Johnson $67,224,000,000 $65,030,000,000 $67,224,000,000 $65,030,000,000 $10,853,000,000 $9,672,000,000 $3.86 $3.49 $121,347,000,000 $113,644,000,000 $64,826,000,000 $57,080,000,000 Johnson & Johnson

2 Pfizer Inc. 58,986,000,000 65,259,000,000 58,986,000,000 65,259,000,000 14,570,000,000 10,009,000,000 1.94 1.27 185,798,000,000 188,002,000,000 81,260,000,000 82,190,000,000 Pfizer Inc.

3 Novartis AG 56,673,000,000 58,566,000,000 56,673,000,000 58,566,000,000 9,618,000,000 9,245,000,000 3.89 3.78 124,216,000,000 117,496,000,000 69,219,000,000 65,940,000,000 Novartis AG

4 F. Hoffmann-La Roche Ltd. 48,521,915,325 45,356,723,899 48,521,915,325 45,356,723,899 10,422,309,907 10,178,095,340 11.90 11.71 69,110,589,741 65,667,057,694 15,456,969,180 12,898,581,636 F. Hoffmann-La Roche Ltd.

5 Merck & Co. 47,267,000,000 48,047,000,000 47,267,000,000 48,047,000,000 6,168,000,000 6,272,000,000 2.00 2.02 106,132,000,000 105,128,000,000 55,463,000,000 56,943,000,000 Merck & Co.

6 Sanofi 44,938,347,300 42,934,915,100 44,938,347,300 42,934,915,100 6,387,065,300 7,320,628,700 4.81 5.52 129,113,361,300 129,448,981,200 73,730,934,200 72,271,437,700 Sanofi

7 GlaxoSmithKline plc 41,901,064,300 43,416,611,100 41,901,064,300 43,416,611,100 7,236,894,500 8,340,263,300 1.45 1.64 65,750,317,500 65,124,124,000 9,210,593,000 12,733,129,600 GlaxoSmithKline plc

8 Abbott Laboratories 39,873,910,000 38,851,259,000 39,873,910,000 38,851,259,000 5,962,900,000 4,728,449,000 3.72 3.01 67,234,944,000 60,276,893,000 26,813,232,000 24,526,145,000 Abbott Laboratories

9 AstraZeneca plc 27,973,000,000 33,591,000,000 27,973,000,000 33,591,000,000 6,327,000,000 10,016,000,000 4.98 7.30 53,534,000,000 52,830,000,000 23,952,000,000 23,472,000,000 AstraZeneca plc

10 Bayer AG 23,933,170,800 22,077,617,100 51,127,384,000 46,971,355,200 3,145,311,400 3,176,173,000 3.81 3.84 66,012,962,400 67,850,513,500 23,877,877,100 24,780,578,900 Bayer AG

11 Eli Lilly and Co. 22,603,400,000 24,286,500,000 22,603,400,000 24,286,500,000 4,088,600,000 4,347,700,000 3.66 3.90 34,398,900,000 33,659,800,000 14,773,900,000 13,535,600,000 Eli Lilly and Co.

12 Teva Pharmaceutical Industries Ltd. 20,317,000,000 18,312,000,000 20,317,000,000 18,312,000,000 1,963,000,000 2,759,000,000 2.25 3.09 50,609,000,000 50,142,000,000 22,867,000,000 22,343,000,000 Teva Pharmaceutical Industries Ltd.

13 Boehringer Ingelheim GmbH 18,891,156,900 16,936,588,900 18,891,156,900 16,936,588,900 1,590,658,300 1,897,988,400 N/A N/A 22,233,211,000 23,992,322,200 7,944,290,200 9,600,529,400 Boehringer Ingelheim GmbH

14 Bristol-Myers Squibb Co. 17,621,000,000 21,244,000,000 17,621,000,000 21,244,000,000 1,960,000,000 3,709,000,000 1.16 2.16 35,897,000,000 32,970,000,000 13,638,000,000 15,867,000,000 Bristol-Myers Squibb Co.

15 Amgen Inc. 17,265,000,000 15,582,000,000 17,265,000,000 15,582,000,000 4,345,000,000 3,683,000,000 5.52 4.04 54,298,000,000 48,871,000,000 19,060,000,000 19,029,000,000 Amgen Inc.

16 Takeda Pharmaceutical Co. 15,532,299,251 15,024,649,151 16,432,067,110 15,922,042,841 1,384,868,629 1,310,140,340 1.75 1.66 41,738,936,372 37,744,328,374 24,748,855,123 24,970,412,578 Takeda Pharmaceutical Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

17 Baxter International Inc. 14,190,000,000 13,893,000,000 14,190,000,000 13,893,000,000 2,326,000,000 2,224,000,000 4.18 3.88 20,390,000,000 19,073,000,000 6,938,000,000 6,585,000,000 Baxter International Inc.

18 Novo Nordisk A/S 13,470,874,624 11,454,369,670 13,470,874,624 11,454,369,670 3,700,148,476 2,951,728,186 6.71 5.18 11,337,488,346 11,169,849,107 7,014,951,141 6,465,246,366 Novo Nordisk A/S

19 Otsuka Holdings Co. 12,129,597,974 11,462,266,540 12,852,748,760 12,182,895,431 1,291,853,962 972,607,365 2.34 1.74 18,773,947,452 17,587,496,043 14,160,979,213 13,376,933,629 Otsuka Holdings Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

20 Astellas Pharma Inc. 10,611,068,904 10,228,838,240 10,611,068,904 10,228,838,240 874,232,35 825,472,196 1.90 1.79 15,253,360,768 14,779,244,487 11,871,351,694 12,149,699,272 Astellas Pharma Inc. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

21 Daiichi Sankyo Co. 10,529,197,003 9,904,790,546 10,529,197,003 9,904,790,546 702,975,625 109,559,987 0.16 0.16 17,348,010,974 16,022,781,471 9,575,540,783 9,317,769,336 Daiichi Sankyo Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

22 Gilead Sciences Inc. 9,702,517,000 8,385,385,000 9,702,517,000 8,385,385,000 2,591,566,000 2,803,637,000 1.64 1.77 21,239,838,000 17,303,134,000 9,550,869,000 6,867,349,000 Gilead Sciences Inc.

23 Merck KGaA 8,847,506,360 8,250,591,580 14,367,232,110 13,214,422,760 744,536,100 794,686,200 3.36 3.59 27,831,119,470 28,446,551,210 13,323,724,260 13,435,083,200 Merck KGaA

24 Mylan Inc. 6,796,110,000 6,129,825,000 6,796,110,000 6,129,825,000 640,850,000 536,810,000 1.52 1.22 11,931,897,000 11,598,143,000 6,231,450,000 5,393,212,000 Mylan Inc.

25 Actavis Inc. 5,914,900,000 4,584,400,000 5,914,900,000 4,584,400,000 97,300,000 260,900,000 0.76 2.06 14,103,500,000 6,698,300,000 3,856,400,000 3,562,500,000 Actavis Inc.

26 Allergan Inc. 5,806,100,000 5,419,100,000 5,806,100,000 5,419,100,000 1,098,800,000 934,500,000 3.58 3.01 9,179,300,000 8,508,600,000 5,837,100,000 5,309,600,000 Allergan Inc.

27 Eisai Co. 5,795,251,662 6,407,449,615 6,053,160,283 6,837,353,593 509,391,158 617,400,021 1.79 2.17 10,448,971,193 10,601,034,083 5,004,779,994 4,467,943,442 Eisai Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

28 Biogen Idec Inc. 5,516,461,000 5,048,634,000 5,516,461,000 5,048,634,000 1,380,033,000 1,234,428,000 5.76 5.04 10,130,118,000 9,049,604,000 6,961,523,000 6,425,499,000 Biogen Idec Inc.

29 Celgene Corp. 5,506,713,000 4,842,070,000 5,506,713,000 4,842,070,000 1,456,180,000 1,317,456,000 3.30 2.85 11,734,306,000 10,005,910,000 5,694,467,000 5,512,727,000 Celgene Corp.

30 CSL Ltd. 5,130,000,000 4,814,000,000 5,130,000,000 4,814,000,000 1,216,000,000 1,024,000,000 2.43 1.97 5,976,000,000 5,901,000,000 3,007,000,000 3,477,000,000 CSL Ltd. (June 13) (June 12) (June 13) (June 12) (June 13) (June 12) (June 13) (June 12) (June 13) (June 12) (June 13) (June 12)

31 Chugai Pharmaceutical Co. 4,901,277,875 4,679,491,356 4,901,277,875 4,679,491,356 603,933,851 441,430,719 1.11 0.81 7,363,066,901 6,683,575,545 6,209,145,577 5,875,695,314 Chugai Pharmaceutical Co.

32 Shire plc 4,681,200,000 4,263,400,000 4,681,200,000 4,263,400,000 745,400,000 865,000,000 1.31 1.51 7,317,200,000 6,380,200,000 3,809,200,000 3,185,000,000 Shire plc

33 UCB S.A. 4,451,785,800 4,174,031,400 4,451,785,800 4,174,031,400 324,046,800 306,044,200 1.81 1.70 12,036,024,000 11,799,418,400 5,907,424,600 6,042,444,100 UCB S.A.

34 Mitsubishi Tanabe Pharma Corp. 4,375,709,613 4,194,987,865 4,423,119,131 4,296,254,089 442,038,620 411,670,360 0.79 0.73 9,146,079,983 8,651,735,781 7,853,962,224 7,648,707,397 Mitsubishi Tanabe Pharma Corp. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

35 Hospira Inc. 4,092,100,000 4,057,100,000 4,092,100,000 4,057,100,000 44,200,000 (9,400,000) 0.27 (0.06) 6,088,600,000 5,779,100,000 3,041,700,000 2,938,000,000 Hospira Inc.

36 Valeant Pharmaceuticals International Inc. 3,546,626,000 2,463,450,000 3,546,626,000 2,463,450,000 (116,025,000) 159,559,000 (0.38) 0.49 17,950,379,000 13,108,119,000 3,717,398,000 3,929,830,000 Valeant Pharmaceuticals International Inc.

37 Grifols S.A. 3,370,271,890 2,308,978,757 3,370,271,890 2,308,978,757 328,389,284 64,588,185 0.96 0.21 7,236,368,817 7,252,476,000 2,418,444,852 2,141,015,785 Grifols S.A.

38 Dainippon Sumitomo Pharma Co. 3,241,521,579 3,271,721,009 3,669,135,802 3,697,319,827 105,972,354 91,052,021 0.27 0.23 6,407,291,337 5,902,817,347 3,652,685,449 3,622,190,567 Dainippon Sumitomo Pharma Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

39 Kyowa Hakko Kirin Co. 3,130,681,533 2,873,202,205 4,173,866,199 4,306,213,981 303,169,632 320,821,849 0.55 0.57 8,510,924,580 8,254,485,091 7,024,091,706 6,951,340,516 Kyowa Hakko Kirin Co.

40 Forest Laboratories Inc. 3,126,125,000 4,586,044,000 3,126,125,000 4,586,044,000 (32,103,000) 979,058,000 (0.12) 3.57 7,629,582,000 7,491,755,000 5,745,255,000 5,676,817,000 Forest Laboratories Inc. (March 13) (March 12) (March 13) (March 12) March 13 (March 12) March 13 (March 12) (March 13) (March 12) (March 13) (March 12)

41 Endo Health Solutions Inc. 3,027,363,000 2,730,121,000 3,027,363,000 2,730,121,000 (740,337,000) 187,613,000 (6.40) 1.55 6,568,559,000 7,292,583,000 1,133,206,000 2,039,591,000 Endo Health Solutions Inc.

42 Taisho Pharmaceutical Co. 3,009,053,498 2,861,981,640 3,009,053,498 2,861,981,640 277,725,018 257,011,713 3.43 3.13 7,137,153,108 6,642,460,694 6,100,643,664 5,683,929,514 Taisho Pharmaceutical Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

43 Shionogi & Co. 2,985,153,530 2,820,249,024 2,985,153,530 2,820,249,024 704,094,123 285,966,023 2.10 0.85 6,066,075,762 5,509,771,025 4,524,343,147 3,961,549,013 Shionogi & Co. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

44 H. Lundbeck A/S 2,555,505,680 2,763,544,077 2,555,505,680 2,763,544,077 201,132,558 394,150,754 1.03 2.01 3,722,765,098 3,545,112,393 2,278,581,541 2,205,724,940 H. Lundbeck A/S

45 Warner Chilcott plc 2,541,000,000 2,728,106,000 2,541,000,000 2,728,106,000 403,000,000 171,146,000 1.61 0.67 4,218,000,000 5,030,029,000 (600,000,000) 69,131,000 Warner Chilcott plc

46 Stada Arzneimittel AG 2,362,841,250 2,205,827,716 2,362,841,250 2,205,827,716 111,230,350 28,336,092 1.88 0.48 3,834,598,807 3,600,320,686 1,159,196,415 1,098,042,869 Stada Arzneimittel AG

47 Ranbaxy Laboratories Ltd. 2,295,839,236 1,868,091,062 2,295,839,236 1,868,091,062 172,899,382 (543,325,651) 0.41 (1.29) 1,247,215,852 1,479,358,628 359,933,858 360,532,884 Ranbaxy Laboratories Ltd.

48 Sun Pharmaceutical Industries Ltd. 2,076,306,114 1,473,598,430 2,076,306,114 1,473,598,430 552,719,535 488,156,640 0.53 0.47 3,868,312,787 3,027,034,576 2,758,899,287 2,248,277,839 Sun Pharmaceutical Industries Ltd. (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

49 Meda AB 1,918,311,897 1,898,377,165 1,918,311,897 1,898,377,165 174,244,326 237,444,810 0.59 0.79 5,397,882,488 5,717,281,198 2,231,656,355 2,210,687,970 Meda AB

50 Actelion Pharmaceuticals Ltd. 1,843,229,178 1,915,391,916 1,843,229,178 1,915,391,916 323,372,081 (156,040,311) 2.74 (1.31) 2,873,292,098 2,913,594,966 1,619,541,431 1,610,807,294 Actelion Pharmaceuticals Ltd.

Notes: N/A = Not applicable; March 13 = fiscal year ended March 31, 2013; March 12 = March 31, 2012; June 13 = June 30, 2013; June 12 = June 30, 2012; For more details about this information, please see the Notes and Methodology on page 8.

October 2013 Med Ad News • 11 Top 50 Companies Ranked By Healthcare R&D Expenditure Top 50 Companies Ranked By Consolidated Revenue Rank Healthcare Healthcare Consolidated Consolidated Company 2012 R&D 2012 R&D 2011 R&D 2012 R&D 2011 Rank Consolidated Consolidated Company 2012 Revenue 2012 Revenue 2011 1 F. Hoffmann-La Roche Ltd. $10,186,626,853 $8,879,172,443 $10,186,626,853 $8,879,172,443 1 Johnson & Johnson $67,224,000,000 $65,030,000,000 2 Novartis AG 9,332,000,000 9,583,000,000 9,332,000,000 9,583,000,000 2 Pfizer Inc. 58,986,000,000 65,259,000,000 3 Merck & Co. 8,168,000,000 8,467,000,000 8,168,000,000 8,467,000,000 3 Novartis AG 56,673,000,000 58,566,000,000 4 Pfizer Inc. 7,870,000,000 9,074,000,000 7,870,000,000 9,074,000,000 4 Bayer AG 51,127,384,000 46,971,355,200 5 Johnson & Johnson 7,665,000,000 7,548,000,000 7,665,000,000 7,548,000,000 5 F. Hoffmann-La Roche Ltd. 48,521,915,325 45,356,723,899 6 Sanofi 6,329,199,800 6,186,464,900 6,329,199,800 6,186,464,900 6 Merck & Co. 47,267,000,000 48,047,000,000 7 GlaxoSmithKline plc 6,290,470,400 6,355,467,700 6,290,470,400 6,355,467,700 7 Sanofi 44,938,347,300 42,934,915,100 8 Eli Lilly and Co. 5,278,100,000 5,020,800,000 5,278,100,000 5,020,800,000 8 GlaxoSmithKline plc 41,901,064,300 43,416,611,100

9 AstraZeneca plc 5,243,000,000 5,523,000,000 5,243,000,000 5,523,000,000 9 Abbott Laboratories 39,873,910,000 38,851,259,000

10 Abbott Laboratories 4,322,182,000 4,129,414,000 4,322,182,000 4,129,414,000 10 AstraZeneca plc 27,973,000,000 33,591,000,000

11 Bristol-Myers Squibb Co. 3,904,000,000 3,839,000,000 3,904,000,000 3,839,000,000 11 Eli Lilly and Co. 22,603,400,000 24,286,500,000

12 Boehringer Ingelheim GmbH 3,594,090,500 3,235,324,400 3,594,090,500 3,235,324,400 12 Teva Pharmaceutical 20,317,000,000 18,312,000,000 Industries Ltd. 13 Amgen Inc. 3,380,000,000 3,167,000,000 3,380,000,000 3,167,000,000 13 Boehringer Ingelheim 18,891,156,900 16,936,588,900 14 Takeda Pharmaceutical Co. 3,359,712,989 2,921,810,700 3,421,884,563 2,974,095,178 GmbH (March 13) (March 12) (March 13) (March 12) 14 Bristol-Myers Squibb Co. 17,621,000,000 21,244,000,000 15 Bayer AG 2,522,935,800 2,504,933,200 3,874,416,700 3,770,258,800 15 Amgen Inc. 17,265,000,000 15,582,000,000 16 Otsuka Holdings Co. 1,936,108,473 1,575,604,094 2,029,798,459 1,680,162,499 (March 13) (March 12) (March 13) (March 12) 16 Takeda Pharmaceutical Co. 16,432,067,110 15,922,042,841 (March 13) (March 12) 17 Daiichi Sankyo Co. 1,931,486,757 1,952,643,242 1,931,486,757 1,952,643,242 17 (March 13) (March 12) (March 13) (March 12) Merck KGaA 14,367,232,110 13,214,422,760 18 Baxter International Inc. 14,190,000,000 13,893,000,000 18 Astellas Pharma Inc. 1,919,953,572 2,003,165,559 1,919,953,572 2,003,165,559 (March 13) (March 12) (March 13) (March 12) 19 Novo Nordisk A/S 13,470,874,624 11,454,369,670

19 Novo Nordisk A/S 1,881,323,159 1,662,235,420 1,881,323,159 1,662,235,420 20 Otsuka Holdings Co. 12,852,748,760 12,182,895,431 (March 13) (March 12) 20 Gilead Sciences Inc. 1,759,945,000 1,229,151,000 1,759,945,000 1,229,151,000 21 Astellas Pharma Inc. 10,611,068,904 10,228,838,240 21 Celgene Corp. 1,724,156,000 1,600,264,000 1,724,156,000 1,600,264,000 (March 13) (March 12)

22 Merck KGaA 1,551,695,530 1,603,903,070 1,943,380,670 1,946,852,600 22 Daiichi Sankyo Co. 10,529,197,003 9,904,790,546 (March 13) (March 12) 23 Biogen Idec Inc. 1,334,919,000 1,219,602,000 1,334,919,000 1,219,602,000 23 Gilead Sciences Inc. 9,702,517,000 8,385,385,000 24 Teva Pharmaceutical Industries Ltd. 1,283,000,000 1,080,000,000 1,283,000,000 1,080,000,000 24 Mylan Inc. 6,796,110,000 6,129,825,000 25 Eisai Co. 1,270,444,233 1,320,481,165 1,270,444,233 1,320,481,165 (March 13) (March 12) (March 13) (March 12) 25 Eisai Co. 6,053,160,283 6,837,353,593 (March 13) (March 12) 26 Baxter International Inc. 1,156,000,000 946,000,000 1,156,000,000 946,000,000 26 Actavis Inc. 5,914,900,000 4,584,400,000 27 UCB S.A. 1,144,451,000 1,000,430,200 1,144,451,000 1,000,430,200 27 Allergan Inc. 5,806,100,000 5,419,100,000 28 Allergan Inc. 989,600,000 902,800,000 989,600,000 902,800,000 28 Biogen Idec Inc. 5,516,461,000 5,048,634,000

29 Shire plc 965,500,000 770,700,000 965,500,000 770,700,000 29 Celgene Corp. 5,506,713,000 4,842,070,000

30 Forest Laboratories Inc. 963,594,000 796,932,000 963,594,000 796,932,000 30 CSL Ltd. 5,130,000,000 4,814,000,000 (March 13) (March 12) (March 13) (March 12) (June 13) (June 12)

31 Mitsubishi Tanabe Pharma Corp. 701,698,850 741,173,367 701,698,850 741,173,367 31 Chugai Pharmaceutical Co. 4,901,277,875 4,679,491,356 (March 13) (March 12) (March 13) (March 12) 32 Shire plc 4,681,200,000 4,263,400,000 32 Chugai Pharmaceutical Co. 690,390,879 699,787,021 690,390,879 699,787,021 33 UCB S.A. 4,451,785,800 4,174,031,400 33 Dainippon Sumitomo Pharma Co. 631,465,654 600,295,452 631,465,654 600,295,452 34 (March 13) (March 12) (March 13) (March 12) Mitsubishi Tanabe Pharma 4,423,119,131 4,296,254,089 Corp. (March 13) (March 12) 34 Shionogi & Co. 559,470,297 565,569,273 559,470,297 565,569,273 35 Kyowa Hakko Kirin Co. 4,173,866,199 4,306,213,981 (March 13) (March 12) (March 13) (March 12) 36 Hospira Inc. 4,092,100,000 4,057,100,000 35 Kyowa Hakko Kirin Co. 517,414,182 557,504,385 561,363,067 600,864,445 37 Dainippon Sumitomo 3,669,135,802 3,697,319,827 36 H. Lundbeck A/S 503,263,009 573,184,628 503,263,009 573,184,628 Pharma Co. (March 13) (March 12)

37 Actelion Pharmaceuticals Ltd. 491,064,306 488,099,605 491,064,306 488,099,605 38 Valeant Pharmaceuticals 3,546,626,000 2,463,450,000 International Inc. 38 CSL Ltd. 427,000,000 370,00,000 427,000,000 370,00,000 (June 13) (June 12) (June 13) (June 12) 39 Grifols S.A. 3,370,271,890 2,308,978,757

39 Actavis Inc. 401,800,000 295,400,000 401,800,000 295,400,000 40 Forest Laboratories Inc. 3,126,125,000 4,586,044,000 (March 13) (March 12) 40 Mylan Inc. 401,341,000 294,728,000 401,341,000 294,728,000 41 Endo Health Solutions Inc. 3,027,363,000 2,730,121,000 41 Meda AB 385,257,158 364,436,438 385,257,158 364,436,438 42 Taisho Pharmaceutical Co. 3,009,053,498 2,861,981,640 42 Hospira Inc. 303,600,000 258,800,000 303,600,000 258,800,000 (March 13) (March 12)

43 Taisho Pharmaceutical Co. 246,185,502 255,682,178 246,185,502 255,682,178 43 Shionogi & Co. 2,985,153,530 2,820,249,024 (March 13) (March 12) (March 13) (March 12) (March 13) (March 12)

44 Endo Health Solutions Inc. 226,120,000 182,286,000 226,120,000 182,286,000 44 H. Lundbeck A/S 2,555,505,680 2,763,544,077

45 Grifols S.A. 160,021,254 114,908,024 160,021,254 114,908,024 45 Warner Chilcott plc 2,541,000,000 2,728,106,000 46 Stada Arzneimittel AG 2,362,841,250 2,205,827,716 46 Sun Pharmaceutical Industries Ltd. 121,557,286 75,106,251 121,557,286 75,106,251 (March 13) (March 12) (March 13) (March 12) 47 Ranbaxy Laboratories Ltd. 2,295,839,236 1,868,091,062

47 Warner Chilcott plc 103,000,000 107,796,000 103,000,000 107,796,000 48 Sun Pharmaceutical 2,076,306,114 1,473,598,430 Industries Ltd. (March 13) (March 12) 48 Ranbaxy Laboratories Ltd. 84,137,343 84,864,531 84,137,343 84,864,531 49 Meda AB 1,918,311,897 1,898,377,165 49 Valeant Pharmaceuticals 79,052,000 65,687,000 79,052,000 65,687,000 International Inc. 50 Actelion Pharmaceuticals 1,843,229,178 1,915,391,916 Ltd. 50 Stada Arzneimittel AG 67,108,549 64,746,351 67,108,549 64,746,351 Notes: N/A = Not applicable; March 13 = fiscal year ended March 31, 2013; Notes: March 13 = fiscal year ended March 31, 2013; March 12 = March 31, 2012; June 13 = June 30, 2013; March 12 = March 31, 2012; June 13 = June 30, 2013; June 12 = June 30, 2012; June 12 = June 30, 2012; For more details about this information, please see the Notes and Methodology on For more details about this information, please see the Notes and Methodology on page 8. page 8.

12 • Med Ad News October 2013 Top 50 Companies Ranked By Net Income Most Profitable Companies: Return On Revenue

Rank Net Income/ Net Income/ Income/ Company Rank Consolidated Net Income/ 2012 (Loss) 2012 (Loss) 2011 Company (loss) as % of 2012 Revenue 2012 (Loss) 2012 revenue 2012 1 Pfizer Inc. $14,570,000,000 $10,009,000,000 1 Novo Nordisk A/S $13,470,874,624 $3,700,148,476 27.47% 2 Johnson & Johnson 10,853,000,000 9,672,000,000

3 F. Hoffmann-La Roche Ltd. 10,422,309,907 10,178,095,340 2 Gilead Sciences Inc. 9,702,517,000 2,591,566,000 26.71

4 Novartis AG 9,618,000,000 9,245,000,000 3 Sun Pharmaceutical 2,076,306,114 552,719,535 26.62 Industries Ltd. 5 GlaxoSmithKline plc 7,236,894,500 8,340,263,300 4 Celgene Corp. 5,506,713,000 1,456,180,000 26.44 6 Sanofi 6,387,065,300 7,320,628,700 5 Amgen Inc. 17,265,000,000 4,345,000,000 25.17 7 AstraZeneca plc 6,327,000,000 10,016,000,000 6 Biogen Idec Inc. 5,516,461,000 1,380,033,000 25.02 8 Merck & Co. 6,168,000,000 6,272,000,000 7 Pfizer Inc. 58,986,000,000 14,570,000,000 24.70 9 Abbott Laboratories 5,962,900,000 4,728,449,000 8 CSL Ltd. 5,130,000,000 1,216,000,000 23.70 10 Amgen Inc. 4,345,000,000 3,683,000,000 9 11 Eli Lilly and Co. 4,088,600,000 4,347,700,000 Shionogi & Co. 2,985,153,530 704,094,123 23.59

12 Novo Nordisk A/S 3,700,148,476 2,951,728,186 10 AstraZeneca plc 27,973,000,000 6,327,000,000 22.62

13 Bayer AG 3,145,311,400 3,176,173,000 11 F. Hoffmann-La Roche Ltd. 48,521,915,325 10,422,309,907 21.48

14 Gilead Sciences Inc. 2,591,566,000 2,803,637,000 12 Allergan Inc. 5,806,100,000 1,098,800,000 18.92

15 Baxter International Inc. 2,326,000,000 2,224,000,000 13 Eli Lilly and Co. 22,603,400,000 4,088,600,000 18.09

16 Teva Pharmaceutical Industries Ltd. 1,963,000,000 2,759,000,000 14 Actelion Pharmaceuticals 1,843,229,178 323,372,081 17.54 Ltd. 17 Bristol-Myers Squibb Co. 1,960,000,000 3,709,000,000 15 GlaxoSmithKline plc 41,901,064,300 7,236,894,500 17.27 18 Boehringer Ingelheim GmbH 1,590,658,300 1,897,988,400 16 Novartis AG 56,673,000,000 9,618,000,000 16.97 19 Celgene Corp. 1,456,180,000 1,317,456,000

20 Takeda Pharmaceutical Co. 1,384,868,629 1,310,140,340 17 Baxter International Inc. 14,190,000,000 2,326,000,000 16.39 (March 13) (March 12) 18 Johnson & Johnson 67,224,000,000 10,853,000,000 16.14 21 Biogen Idec Inc. 1,380,033,000 1,234,428,000 19 Shire plc 4,681,200,000 745,400,000 15.92 22 Otsuka Holdings Co. 1,291,853,962 972,607,365 (March 13) (March 12) 20 Warner Chilcott plc 2,541,000,000 403,000,000 15.86

23 CSL Ltd. 1,216,000,000 1,024,000,000 21 Abbott Laboratories 39,873,910,000 5,962,900,000 14.95 (June 13) (June 12) 22 Sanofi 44,938,347,300 6,387,065,300 14.21 24 Allergan Inc. 1,098,800,000 934,500,000 23 Merck & Co. 47,267,000,000 6,168,000,000 13.05 25 Astellas Pharma Inc. 874,232,352 825,472,196 (March 13) (March 12) 24 Chugai Pharmaceutical 4,901,277,875 603,933,851 12.32 Co. 26 Shire plc 745,400,000 865,000,000 25 Bristol-Myers Squibb Co. 17,621,000,000 1,960,000,000 11.12 27 Merck KGaA 744,536,100 794,686,200 26 Otsuka Holdings Co. 12,852,748,760 1,291,853,962 10.05 28 Shionogi & Co. 704,094,123 285,966,023 (March 13) (March 12) 27 Mitsubishi Tanabe Pharma 4,423,119,131 442,038,620 9.99 Corp. 29 Daiichi Sankyo Co. 702,975,625 109,559,987 (March 13) (March 12) 28 Grifols S.A. 3,370,271,890 328,389,284 9.74

30 Mylan Inc. 640,850,000 536,810,000 29 Teva Pharmaceutical 20,317,000,000 1,963,000,000 9.66 Industries Ltd. 31 Chugai Pharmaceutical Co. 603,933,851 441,430,719 30 Mylan Inc. 6,796,110,000 640,850,000 9.43 32 Sun Pharmaceutical Industries Ltd. 552,719,535 488,156,640 (March 13) (March 12) 31 Taisho Pharmaceutical Co. 3,009,053,498 277,725,018 9.23 33 Eisai Co. 509,391,158 617,400,021 32 Meda AB 1,918,311,897 174,244,326 9.08 (March 13) (March 12) 33 Takeda Pharmaceutical 16,432,067,110 1,384,868,629 8.43 34 Mitsubishi Tanabe Pharma Corp. 442,038,620 411,670,360 Co. (March 13) (March 12)

35 Warner Chilcott plc 403,000,000 171,146,000 34 Boehringer Ingelheim 18,891,156,900 1,590,658,300 8.42 GmbH 36 Grifols S.A. 328,389,284 64,588,185 34 Eisai Co. 6,053,160,283 509,391,158 8.42 37 UCB S.A. 324,046,800 306,044,200 36 Astellas Pharma Inc. 10,611,068,904 874,232,352 8.24 38 Actelion Pharmaceuticals Ltd. 323,372,081 (156,040,311) 37 H. Lundbeck A/S 2,555,505,680 201,132,558 7.87 39 Kyowa Hakko Kirin Co. 303,169,632 320,821,849 38 Ranbaxy Laboratories Ltd. 2,295,839,236 172,899,382 7.53 40 Taisho Pharmaceutical Co. 277,725,018 257,011,713 (March 13) (March 12) 39 UCB S.A. 4,451,785,800 324,046,800 7.28

41 H. Lundbeck A/S 201,132,558 394,150,754 40 Kyowa Hakko Kirin Co. 4,173,866,199 303,169,632 7.26

42 Meda AB 174,244,326 237,444,810 41 Daiichi Sankyo Co. 10,529,197,003 702,975,625 6.68 43 Ranbaxy Laboratories Ltd. 172,899,382 (543,325,651) 42 Bayer AG 51,127,384,000 3,145,311,400 6.15 44 Stada Arzneimittel AG 111,230,350 28,336,092 43 Merck KGaA 14,367,232,110 744,536,100 5.18 45 Dainippon Sumitomo Pharma Co. 105,972,354 91,052,021 44 (March 13) (March 12) Stada Arzneimittel AG 2,362,841,250 111,230,350 4.71 45 46 Actavis Inc. 97,300,000 260,900,000 Dainippon Sumitomo 3,669,135,802 105,972,354 2.89 Pharma Co. 47 Hospira Inc. 44,200,000 (9,400,000) 46 Actavis Inc. 5,914,900,000 97,300,000 1.64 48 Forest Laboratories Inc. (32,103,000) 979,058,000 March 13 (March 12) 47 Hospira Inc. 4,092,100,000 44,200,000 1.08

49 Valeant Pharmaceuticals International (116,025,000) 159,559,000 48 Forest Laboratories Inc. 3,126,125,000 -32,103,000 -1.03 Inc. 49 Valeant Pharmaceuticals 3,546,626,000 -116,025,000 -3.27 50 Endo Health Solutions Inc. (740,337,000) 187,613,000 International Inc.

Notes: N/A = Not applicable; March 13 = fiscal year ended March 31, 2013; March 12 = March 31, 50 Endo Health Solutions Inc. 3,027,363,000 -740,337,000 -24.45 2012; June 13 = June 30, 2013; June 12 = June 30, 2012; For more details about this information, please see the Notes and Methodology on page 8. Note: For more details about this information, please see the Notes and Methodology on page 8.

14 • Med Ad News October 2013 Top 50 Companies Ranked By Total Assets Top 50 Companies Ranked By Shareholders’ Equity Rank Shareholders’ Shareholders’ Rank Company Company Total Assets 2012 Total Assets 2011 2012 Equity 2012 Equity 2011 2012 1 Pfizer Inc. $81,260,000,000 $82,190,000,000 1 Pfizer Inc. $185,798,000,000 $188,002,000,000 2 Sanofi 73,730,934,200 72,271,437,700 2 Sanofi 129,113,361,300 129,448,981,200 3 Novartis AG 69,219,000,000 65,940,000,000 3 Novartis AG 124,216,000,000 117,496,000,000 4 Johnson & Johnson 64,826,000,000 57,080,000,000 4 Johnson & Johnson 121,347,000,000 113,644,000,000 5 Merck & Co. 55,463,000,000 56,943,000,000 5 Merck & Co. 106,132,000,000 105,128,000,000 6 Abbott Laboratories 26,813,232,000 24,526,145,000 6 F. Hoffmann-La Roche Ltd. 69,110,589,741 65,667,057,694 7 Takeda Pharmaceutical Co. 24,748,855,123 24,970,412,578 7 Abbott Laboratories 67,234,944,000 60,276,893,000 (March 13) (March 12)

8 Bayer AG 66,012,962,400 67,850,513,500 8 AstraZeneca plc 23,952,000,000 23,472,000,000

9 GlaxoSmithKline plc 65,750,317,500 65,124,124,000 9 Bayer AG 23,877,877,100 24,780,578,900

10 Amgen Inc. 54,298,000,000 48,871,000,000 10 Teva Pharmaceutical Industries Ltd. 22,867,000,000 22,343,000,000 11 AstraZeneca plc 53,534,000,000 52,830,000,000 11 Amgen Inc. 19,060,000,000 19,029,000,000 12 Teva Pharmaceutical Industries Ltd. 50,609,000,000 50,142,000,000 12 F. Hoffmann-La Roche Ltd. 15,456,969,180 12,898,581,636 13 Takeda Pharmaceutical Co. 41,738,936,372 37,744,328,374 (March 13) (March 12) 13 Eli Lilly and Co. 14,773,900,000 13,535,600,000

14 Bristol-Myers Squibb Co. 35,897,000,000 32,970,000,000 14 Otsuka Holdings Co. 14,160,979,213 13,376,933,629 (March 13) (March 12) 15 Eli Lilly and Co. 34,398,900,000 33,659,800,000 15 Bristol-Myers Squibb Co. 13,638,000,000 15,867,000,000 16 Merck KGaA 27,831,119,470 28,446,551,210 16 Merck KGaA 13,323,724,260 13,435,083,200 17 Boehringer Ingelheim GmbH 22,233,211,000 23,992,322,200 17 Astellas Pharma Inc. 11,871,351,694 12,149,699,272 18 Gilead Sciences Inc. 21,239,838,000 17,303,134,000 (March 13) (March 12) 19 Baxter International Inc. 20,390,000,000 19,073,000,000 18 Daiichi Sankyo Co. 9,575,540,783 9,317,769,336 20 Otsuka Holdings Co. 18,773,947,452 17,587,496,043 (March 13) (March 12) (March 13) (March 12) 19 Gilead Sciences Inc. 9,550,869,000 6,867,349,000 21 Valeant Pharmaceuticals 17,950,379,000 13,108,119,000 20 GlaxoSmithKline plc 9,210,593,000 12,733,129,600 International Inc. 21 Boehringer Ingelheim GmbH 7,944,290,200 9,600,529,400 22 Daiichi Sankyo Co. 17,348,010,974 16,022,781,471 (March 13) (March 12) 22 Mitsubishi Tanabe Pharma Corp. 7,853,962,224 7,648,707,397 (March 13) (March 12) 23 Astellas Pharma Inc. 15,253,360,768 14,779,244,487 (March 13) (March 12) 23 Kyowa Hakko Kirin Co. 7,024,091,706 6,951,340,516

24 Actavis Inc. 14,103,500,000 6,698,300,000 24 Novo Nordisk A/S 7,014,951,141 6,465,246,366

25 UCB S.A. 12,036,024,000 11,799,418,400 25 Biogen Idec Inc. 6,961,523,000 6,425,499,000

26 Mylan Inc. 11,931,897,000 11,598,143,000 26 Baxter International Inc. 6,938,000,000 6,585,000,000

27 Celgene Corp. 11,734,306,000 10,005,910,000 27 Mylan Inc. 6,231,450,000 5,393,212,000

28 Novo Nordisk A/S 11,337,488,346 11,169,849,107 28 Chugai Pharmaceutical Co. 6,209,145,577 5,875,695,314

29 Eisai Co. 10,448,971,193 10,601,034,083 29 Taisho Pharmaceutical Co. 6,100,643,664 5,683,929,514 (March 13) (March 12) (March 13) (March 12)

30 Biogen Idec Inc. 10,130,118,000 9,049,604,000 30 UCB S.A. 5,907,424,600 6,042,444,100

31 Allergan Inc. 9,179,300,000 8,508,600,000 31 Allergan Inc. 5,837,100,000 5,309,600,000

32 Mitsubishi Tanabe Pharma Corp. 9,146,079,983 8,651,735,781 32 Forest Laboratories Inc. 5,745,255,000 5,676,817,000 (March 13) (March 12) (March 13) (March 12)

33 Kyowa Hakko Kirin Co. 8,510,924,580 8,254,485,091 33 Celgene Corp. 5,694,467,000 5,512,727,000

34 Forest Laboratories Inc. 7,629,582,000 7,491,755,000 34 Eisai Co. 5,004,779,994 4,467,943,442 (March 13) (March 12) (March 13) (March 12)

35 Chugai Pharmaceutical Co. 7,363,066,901 6,683,575,545 35 Shionogi & Co. 4,524,343,147 3,961,549,013 (March 13) (March 12) 36 Shire plc 7,317,200,000 6,380,200,000 36 Actavis Inc. 3,856,400,000 3,562,500,000 37 Grifols S.A. 7,236,368,817 7,252,476,000 37 Shire plc 3,809,200,000 3,185,000,000 38 Taisho Pharmaceutical Co. 7,137,153,108 6,642,460,694 (March 13) (March 12) 38 Valeant Pharmaceuticals 3,717,398,000 3,929,830,000 International Inc. 39 Endo Health Solutions Inc. 6,568,559,000 7,292,583,000 39 Dainippon Sumitomo Pharma Co. 3,652,685,449 3,622,190,567 40 Dainippon Sumitomo Pharma Co. 6,407,291,337 5,902,817,347 (March 13) (March 12) (March 13) (March 12) 40 Hospira Inc. 3,041,700,000 2,938,000,000 41 Hospira Inc. 6,088,600,000 5,779,100,000 41 CSL Ltd. 3,007,000,000 3,477,000,000 42 Shionogi & Co. 6,066,075,762 5,509,771,025 (June 13) (June 12) (March 13) (March 12) 42 Sun Pharmaceutical Industries Ltd. 2,758,899,287 2,248,277,839 43 CSL Ltd. 5,976,000,000 5,901,000,000 (March 13) (March 12) (June 13) (June 12) 43 Grifols S.A. 2,418,444,852 2,141,015,785 44 Meda AB 5,397,882,488 5,717,281,198 44 H. Lundbeck A/S 2,278,581,541 2,205,724,940 45 Warner Chilcott plc 4,218,000,000 5,030,029,000 45 Meda AB 2,231,656,355 2,210,687,970 46 Sun Pharmaceutical Industries Ltd. 3,868,312,787 3,027,034,576 (March 13) (March 12) 46 Actelion Pharmaceuticals Ltd. 1,619,541,431 1,610,807,294

47 Stada Arzneimittel AG 3,834,598,807 3,600,320,686 47 Stada Arzneimittel AG 1,159,196,415 1,098,042,869

48 H. Lundbeck A/S 3,722,765,098 3,545,112,393 48 Endo Health Solutions Inc. 1,133,206,000 2,039,591,000

49 Actelion Pharmaceuticals Ltd. 2,873,292,098 2,913,594,966 49 Ranbaxy Laboratories Ltd. 359,933,858 360,532,884

50 Ranbaxy Laboratories Ltd. 1,247,215,852 1,479,358,628 50 Warner Chilcott plc (600,000,000) 69,131,000

Notes: March 13 = fiscal year ended March 31, 2013; March 12 = March 31, 2012; Notes: N/A = Not applicable; March 13 = fiscal year ended March 31, 2013; June 13 = June 30, 2013; June 12 = June 30, 2012; March 12 = March 31, 2012; June 13 = June 30, 2013; June 12 = June 30, 2012; For more details about this information, please see the Notes and Methodology on page 8. For more details about this information, please see the Notes and Methodology on page 8.

16 • Med Ad News October 2013 Top 50 Companies Ranked By Employees Top 50 Companies ranked by Market Capitalization

Rank Company Employees 2012 Employees 2011 Market 2012 Ticker Symbols Rank Capitalization Company (not all global stock 2012 as of Sept. 19-26, 1 Novartis AG 127,724 123,686 exchanges are listed) 2013 ($ in millions) 2 Johnson & Johnson 127,600 117,900 1 Johnson & Johnson $252,720 NYSE: JNJ 3 Sanofi 111,974 113,719 2 Roche Holding Ltd. 224,670 SIX: ROG; PINK: RHHBY 4 Bayer AG 110,500 111,800 3 Pfizer Inc. 191,790 NYSE: PFE 5 GlaxoSmithKline plc 99,488 97,389

6 Pfizer Inc. 91,500 103,700 4 Novartis AG 187,100 SIX: NOVZn; NYSE: NVS

7 Abbott Laboratories 91,000 91,000 5 Merck & Co. 140,500 NYSE: MRK

8 Merck & Co. 83,000 86,000 6 Sanofi 135,370 EPA: SAN; NYSE: SNY

9 F. Hoffmann-La Roche Ltd. 82,089 80,129 7 GlaxoSmithKline plc 122,410 LSE: GSK.L; NYSE: GSK

10 AstraZeneca plc 53,500 59,800 8 Bayer AG 98,200 PINK: BAYRY; ETR: BAYN

11 Baxter International Inc. 51,000 48,500 9 Gilead Sciences Inc. 97,750 Nasdaq: GILD

12 Boehringer Ingelheim GmbH 46,228 44,094 10 Novo Nordisk A/S 92,800 CPH: NOVO-B; NYSE: NVO

13 Teva Pharmaceutical Industries Ltd. 45,948 45,754 11 Amgen Inc. 88,030 Nasdaq: AMGN 14 Merck KGaA 38,847 40,676 12 Bristol-Myers Squibb Co. 77,010 NYSE: BMY 15 Eli Lilly and Co. 38,350 38,080 13 AstraZeneca plc 65,210 LON: AZN; NYSE: AZN 16 Novo Nordisk A/S 34,731 32,632 14 Celgene Corp. 61,630 Nasdaq: CELG 17 Daiichi Sankyo Co. 32,229 31,929 (March 13) (March 12) 15 Biogen Idec Inc. 58,970 Nasdaq: BIIB

18 Takeda Pharmaceutical Co. 30,481 30,305 16 Eli Lilly and Co. 58,260 NYSE: LLY (March 13) (March 12) 17 Abbott Laboratories 54,850 NYSE: ABT 19 Bristol-Myers Squibb Co. 28,000 27,000 18 Baxter International Inc. 38,850 NYSE: BAX 20 Otsuka Holdings Co. 25,330 24,595 (March 13) (March 12) 19 Takeda Pharmaceutical Co. 37,690 TYO: 4502; PINK: TKPYY

21 Mylan Inc. 20,000+ 18,000+ 20 Valeant Pharmaceuticals 34,820 NYSE: VRX International Inc. 22 Amgen Inc. 18,000 17,800 21 Teva Pharmaceutical 31,870 TLV: TEVA 23 Actavis Inc. 17,700 6,686 Industries Ltd. NYSE: TEVA 24 Astellas Pharma Inc. 17,454 17,085 22 CSL Ltd. 29,780 ASX: CSL; OTC: CMXHY (March 13) (March 12) 23 Allergan Inc. 27,500 NYSE: AGN 25 Hospira Inc. 16,000 15,000 24 26 Ranbaxy Laboratories Ltd. 14,600+ 14,000 Merck KGaA 24,830 ETR: MRK

27 Sun Pharmaceutical Industries Ltd. 13,000+ 13,000+ 25 Astellas Pharma Inc. 22,900 TYO: 4503; OTC: ALPMY (March 13) (March 12) 26 Shire plc 22,630 LON: SHP; Nasdaq: SHPG 28 Grifols S.A. 11,418 11,259 27 Sun Pharmaceutical Industries Ltd. 19,153 NSE: SUNPHARMA 29 CSL Ltd. 11,285 10,515 BSE: 524715 (June 13) (June 12) 28 Actavis Inc. 18,040 NYSE: ACT 30 Allergan Inc. 10,800 10,000 29 Otsuka Holdings Co. 15,870 TYO: 4578; OTC: OTSKY 31 Eisai Co. 10,495 10,730 30 Mylan Inc. 14,760 Nasdaq: MYL (March 13) (March 12) 31 Daiichi Sankyo Co. 13,130 TYO: 4568; OTC: DSNKY 32 UCB S.A. 9,048 8,506

33 Mitsubishi Tanabe Pharma Corp. 8,835 9,180 32 Grifols S.A. 12,758 MCE: GRF.MC (March 13) (March 12) NasdaqGS: GRFS 33 Eisai Co. 11,880 TYO: 4523; OTC: ESALY 34 Stada Arzneimittel AG 7,814 7,826 34 Forest Laboratories Inc. 11,620 NYSE: FRX 35 Kyowa Hakko Kirin Co. 7,243 7,229

36 Dainippon Sumitomo Pharma Co. 7,218 7,601 35 Chugai Pharmaceutical Co. 11,113 TYO: 4519; OTC: CHGCY (March 13) (March 12) 36 UCB S.A. 10,830 EBR: UCB; OTC: UCBJF 37 Valeant Pharmaceuticals 7,000 6,900 37 Actelion Ltd. 7,860 SIX: ATLN; PINK: ALIOF International Inc. 38 Mitsubishi Tanabe Pharma Corp. 7,830 TYO: 4508; OTC: MTZXF 38 Chugai Pharmaceutical Co. 6,836 6,779

39 Taisho Pharmaceutical Co. 6,370 6,003 39 Hospira Inc. 6,820 NYSE: HSP (March 13) (March 12) 40 Shionogi & Co. 6,700 TYO: 4507; OTC: SGIOF 40 Shionogi & Co. 6,082 6,132 (March 13) (March 12) 41 Taisho Pharmaceutical Co. 6,010 TYO: 4581; OTC: TSOPF

41 Biogen Idec Inc. 5,950 5,000 42 Kyowa Hakko Kirin Co. 5,912 TYO: 4151; OTC: KYKOF

42 Forest Laboratories Inc. 5,800 5,700 43 Warner Chilcott plc 5,540 Nasdaq: WCRX; FRA: G3LA (March 13) (March 12) 44 Endo Health Solutions Inc. 5,180 Nasdaq: ENDP 43 H. Lundbeck A/S 5,639 5,690 45 Dainippon Sumitomo Pharma Co. 5,120 TYO: 4506; PINK: DNPUY 44 Shire plc 5,367 5,251 46 H. Lundbeck A/S 4,160 CPH: LUN; PINK: HLUKF 45 Gilead Sciences Inc. 5,000 4,500 47 Meda AB 3,630 STO: MEDA-A; OTC: MDABY 46 Celgene Corp. 4,700 4,460

47 Endo Health Solutions Inc. 4,629 4,566 48 Stada Arzneimittel AG 2,760 ETR: SAZ; PINK: STDAF

48 Meda AB 2,900 2,623 49 Ranbaxy Laboratories Ltd. 2,160 BSE: 500359; NSE: RANBAXY; OTC: RBXZF 49 Actelion Pharmaceuticals Ltd. 2,433 2,570 — Boehringer Ingelheim GmbH N/A N/A 50 Warner Chilcott plc 2,100 2,200

Notes: March 13 = fiscal year ended March 31, 2013; March 12 = March 31, 2012; Note: N/A = not applicable June 13 = June 30, 2013; June 12 = June 30, 2012; For more details about this information, please see the Notes and Methodology on page 8. Sources: Yahoo! Finance (finance.yahoo.com), Google Finance (google.com/finance), and others

18 • Med Ad News October 2013 Top 50 Companies: Headquarters and Year Established Company Headquarters Year Established United States Ranbaxy Laboratories Ltd. Gurgaon 1962 Company Headquarters Year Established Sun Pharmaceutical Industries Ltd. Mumbai 1983 Pfizer Inc. , NY 1849 Middle East Eli Lilly and Co. Indianapolis, IN 1876

Johnson & Johnson New Brunswick, NJ 1887 Company Headquarters Year Established

Abbott Laboratories Abbott Park, IL 1888 Teva Pharmaceutical Industries Ltd. Petach Tikva, Israel 1901 Merck & Co. Whitehouse Station, NJ 1891

Endo Health Solutions Inc. Malvern, PA 1920 Notes for Top 50 Company Mergers & Acquisitions Baxter International Inc. Deerfield, IL 1931 Throughout the Decades Allergan Inc. Irvine, CA 1950 • Abbott Laboratories completed the acquisition of Solvay Pharmaceuticals on Feb. 16, 2010. Forest Laboratories Inc. New York, NY 1956 Abbott completed the separation of its research-based pharmaceuticals business, which became AbbVie Inc., on Jan. 2, 2013. Mylan Inc. Canonsburg, PA 1961

Amgen Inc. Thousand Oaks, CA 1980 • Actavis Group, founded in 1956, was acquired by Watson Pharmaceuticals Inc., founded in 1985, on Oct. 31, 2012. The surviving entity is named Actavis Inc. Celgene Corp. Summit, NJ 1980

Actavis Inc. Parsippany, NJ 1985 • Astellas was formed by the April 1, 2005, merger of Fujisawa Pharmaceutical Co., founded in 1894, and Yamanouchi Pharmaceutical Co., founded in 1923. Gilead Sciences Inc. Foster City, CA 1987 • AstraZeneca was formed by the April 5, 1999, merger of Astra AB, founded in 1913, and Group Bristol-Myers Squibb Co. New York, NY 1989 plc, founded in 1993. Biogen Idec Inc. Weston, MA 2003 • Bayer in June 2006 acquired a majority of the shares of Schering AG, which was subsequently renamed Hospira Inc. Lake Forest, IL 2003 Bayer Schering Pharma AG and fully consolidated in the Bayer Group financial statements.

Europe • Biogen Idec was formed by the 2003 merger of Biogen Inc., founded in 1978, and Idec Pharmaceuticals Company Headquarters Year Established Corp., founded in 1985.

Merck KGaA Darmstadt, Germany 1668 • Bristol-Myers Squibb was formed in 1989 through the merger of Bristol-Myers Co., formed in 1887, and Squibb Corp., founded in 1858. Bayer AG Leverkusen, Germany 1863

Boehringer Ingelheim GmbH Ingelheim, Germany 1885 • Daiichi Sankyo was formed by the Sept. 28, 2005, merger of Daiichi Pharmaceutical Co., founded in 1915, and Sankyo Co., founded in 1899. Stada Arzneimittel AG Bad Vilbel, Germany 1895

F. Hoffmann-La Roche Ltd. Basel, Switzerland 1896 • Dainippon Sumitomo was formed on Oct. 1, 2005, through the merger of Dainippon Pharmaceutical Co., founded in 1897, and Sumitomo Pharmaceuticals Co., established in 1984 through the consolidation of the H. Lundbeck A/S Copenhagen, Denmark 1915 pharmaceuticals operations of Sumitomo Chemical Co. and the pharmaceuticals division of Inabata & Co.

UCB S.A. Brussels, Belgium 1928 • GlaxoSmithKline was formed in 2000 through the merger of Glaxo Wellcome plc and SmithKline Beecham Grifols S.A. Barcelona, Spain 1940 plc. Glaxo Wellcome was formed in 1994 through the merger of Glaxo, founded in 1973, and Wellcome, founded in 1880. SmithKline Beecham was formed in 1989 through the merger of SmithKline Beckman Meda AB Solna, 1954 Corp., founded in 1830, and Beecham Group plc.

Warner Chilcott plc Dublin, Ireland 1968 • Kyowa Hakko Kirin was formed on Oct. 1, 2008, via the merger of Kyowa Hakko Kogyo Co. and Kirin Shire plc Dublin, Ireland 1986 Pharma Co. Kyowa Hakko Kogyo was established in 1949 as a secondary company of Kyowa Sangyo Co. as part of industrial readjustment plans. Kirin Pharma was launched in 2007 to accompany the adoption by Novo Nordisk A/S Bagsvaerd, Denmark 1989 Kirin Brewery Co. of a pure holding-company system; Kirin Brewery was founded in 1885 under the original name of Japan Brewery Co. GlaxoSmithKline plc Basel, Switzerland 1996

Actelion Pharmaceuticals Ltd. Allschwil, Switzerland 1997 • Merck & Co. merged on Nov. 3, 2010, with Schering-Plough Corp. Merck was founded in 1891. AstraZeneca plc , 1999 Schering-Plough was formed in 1971 through the merger of Schering Corp., founded in 1928, and Plough Inc., founded in 1908. GlaxoSmithKline plc Brentford, United Kingdom 2000

Sanofi Paris, France 2004 • Mitsubishi Tanabe was formed on Oct. 1, 2007, via the merger of Mitsubishi Pharma Corp. and Tanabe Seiyaku Co., which was established in 1678. Mitsubishi Pharma was formed in 2001 through the merger of Japan Welfide Corp., founded in 1940, and Mitsubishi-Tokyo Pharmaceuticals Corp., founded in 1999.

Company Headquarters Year Established • Novartis was formed in 1996 through the merger of Ciba-Geigy, founded in 1884, and Sandoz, founded in 1886. Novartis completed majority ownership of Inc. on Aug. 26, 2010. Takeda Pharmaceutical Co. Osaka 1781

Shionogi & Co. Osaka 1878 • Novo Nordisk was formed in 1989 through the merger of Nordisk Gentofte AS, founded in 1923, and Novo Industri AS, founded in 1925. Taisho Pharmaceutical Co. Tokyo 1912

Chugai Pharmaceutical Co. Tokyo 1925 • Pfizer merged on Oct. 15, 2009, with , which was founded in 1926. Pfizer merged on June 19, 2000, with Warner-Lambert Co., which was founded in 1920. Pfizer merged on April 16, 2003, with Eisai Co. Tokyo 1941 Pharmacia Corp. Pharmacia was formed by the March 31, 2000, merger of Pharmacia & Inc. and Monsanto Co., founded in 1901. Pharmacia & Upjohn was founded in 1995 through the merger of Otsuka Holdings Co. Tokyo 1964 Pharmacia, founded in 1911, and The Upjohn Co., founded in 1886. Pfizer completed the acquisition of Inc. on Feb. 28, 2011. Astellas Pharma Inc. Tokyo 2005

Daiichi Sankyo Co. Tokyo 2005 • Roche acquired Inc. on March 26, 2009. Roche was founded in 1896. Genentech was Dainippon Sumitomo Pharma Co. Osaka 2005 founded in 1976.

Mitsubishi Tanabe Pharma Corp. Osaka 2007 • Sanofi was previously known as Sanofi-Aventis SA until May 2011. Sanofi-Aventis was formed Aug. 20, Kyowa Hakko Kirin Co. Tokyo 2008 2004, through the merger of Sanofi-Synthelabo SA and Aventis SA. Sanofi-Synthelabo was formed in 1999 through the merger of Sanofi SA, founded in 1970, and Synthelabo SA, founded in 1973. Aventis was Australia formed in 1999 by the merger of Hoechst AG, founded in 1863, and Rhone-Poulenc SA, founded in 1895. Sanofi-Aventis completed the acquisition of Genzyme Corp. on April 8, 2011. Company Headquarters Year Established • Takeda acquired Nycomed A/S on Sept. 30, 2011. Nycomed was founded in 1874. CSL Ltd. Melbourne 1916 • Teva acquired Inc. on Oct. 14, 2011. Cephalon was founded in 1987. Canada

Company Headquarters Year Established • Valeant Pharmaceuticals International was acquired by Biovail Corp. on Sept. 28, 2010. Valeant survived as a wholly owned subsidiary of Biovail. In connection with the merger, Biovail was renamed Valeant Valeant Pharmaceuticals Pharmaceuticals International Inc. Biovail was formed under the Business Corporations Act (Ontario) on Feb. Laval 2000 International Inc. 18, 2000, as a result of the amalgamation of TXM Corp. and Biovail Corporation International.

October 2013 Med Ad News • 19 Top 50 Companies: Business Segments

Company Segment

Abbott Laboratories (pre-AbbVie separation) Pharmaceuticals, biologics, branded generics, devices, diagnostics, nutritional products, vascular products

Actavis Inc. Generics, pharmaceuticals, biosimilars

Actelion Pharmaceuticals Ltd. Biopharmaceuticals

Allergan Inc. Pharmaceuticals, biologics, medical devices, over-the-counter products

Amgen Inc. Human therapeutics

Astellas Pharma Inc. Pharmaceuticals and related products, other businesses

AstraZeneca plc Pharmaceuticals, biopharmaceuticals

Baxter International Inc. Bioscience, delivery, renal

Bayer AG Pharmaceuticals; consumer healthcare; animal health; devices and contrast agents; material science; crop science; business, technology and chemical-industry services

Biogen Idec Inc. Biopharmaceuticals

Boehringer Ingelheim GmbH Pharmaceuticals, consumer healthcare, biopharmaceuticals, biosimilars, contract manufacturing, animal health

Bristol-Myers Squibb Co. Pharmaceuticals, biopharmaceuticals

Celgene Corp. Biopharmaceuticals

Chugai Pharmaceutical Co. Pharmaceuticals

CSL Ltd. Plasma protein biotherapeutics, plasma collection, biological products, , prescription pharmaceuticals, donated plasma collection and testing, in vitro diagnostics, immunohematology

Daiichi Sankyo Co. Pharmaceuticals, consumer health, generics

Dainippon Sumitomo Pharma Co. Pharmaceuticals; food ingredients, food additives, and chemical product materials; animal health products; diagnostics and research materials

Eisai Co. Pharmaceuticals, consumer healthcare, diagnostics, generics, food additives, chemicals, other

Endo Health Solutions Inc. Branded and generic pharmaceuticals

Forest Laboratories Inc. Pharmaceuticals

Gilead Sciences Inc. Biopharmaceuticals

GlaxoSmithKline plc Pharmaceuticals, vaccines, consumer healthcare

Grifols S.A. Bioscience, diagnostic, hospital

Hospira Inc. Specialty injectable pharmaceuticals (primarily generics), other pharmaceuticals (primarily large volume I.V. solutions, nutritionals and contract manufacturing services), medication management Johnson & Johnson Pharmaceuticals, medical devices and diagnostics, consumer healthcare

Kyowa Hakko Kirin Co. Pharmaceuticals, bio-chemicals, chemicals, other

Lilly and Co., Eli Pharmaceuticals, animal health

Lundbeck A/S, H. Pharmaceuticals

Meda AB Branded generics, original prescription pharmaceuticals and specialty products, OTC products, med-tech products

Merck & Co. Pharmaceuticals, vaccines, biologicals, consumer healthcare, animal health

Merck KGaA Biopharmaceuticals, pharmaceuticals, OTC products, liquid crystals, pigments and cosmetics, bioscience, process solutions and lab solutions

Mitsubishi Tanabe Pharma Corp. Pharmaceuticals, vaccines, OTC drugs, fine chemicals, real-estate leasing, information services, advertising, other

Mylan Inc. Generics, active pharmaceutical ingredients, pharmaceuticals

Novartis AG Pharmaceuticals, vaccines and diagnostics, generics, OTC medicines, animal health, eye care

Novo Nordisk A/S Pharmaceuticals for diabetes, biopharmaceuticals

Otsuka Holdings Co. Pharmaceuticals, nutraceuticals, consumer products, chemical goods, pharmaceutical intermediates, logistics, electronic devices, other

Pfizer Inc. Pharmaceuticals, biopharmaceuticals, vaccines, consumer healthcare

Ranbaxy Laboratories Ltd. Generics, pharmaceuticals

Roche Ltd., F. Hoffmann-La Pharmaceuticals, biotechnology, diagnostics

Sanofi Pharmaceuticals, vaccines, generics, consumer healthcare, animal health

Shionogi & Co. Pharmaceuticals, contract manufacturing, consumer healthcare, diagnostics, other businesses

Shire plc Pharmaceuticals, biopharmaceuticals

Stada Arzneimittel AG Generics, pharmaceuticals, active pharmaceutical ingredients

Sun Pharmaceutical Industries Ltd. Generics, branded generics, active pharmaceutical ingredients

Taisho Pharmaceutical Co. Pharmaceuticals, consumer healthcare, health foods, other

Takeda Pharmaceutical Co. Pharmaceuticals, consumer healthcare, other

Teva Pharmaceutical Industries Ltd. Generics, active pharmaceutical ingredients, pharmaceuticals, animal health

UCB S.A. Biopharmaceuticals

Valeant Pharmaceuticals International Inc. Generic, branded, and OTC products

Warner Chilcott plc Specialty pharmaceuticals

20 • Med Ad News October 2013